SCHEMBL8673222

SCHEMBL8673222

OC[C](CO)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
MAPK1 P28482 2/20 0.43
CYP3A4 P08684 2/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 3/20 0.43
CES2 O00748 2/20 0.43
ALDH1A1 P00352 2/20 0.43
DAO P14920 1/20 0.43
NAPRT Q6XQN6 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
NCOR2 Q9Y618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1254294 0.84 ATM (0.48) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL5399187 0.80 POLB (0.36) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL5390647 0.80 CES2 (0.50) CES1TDP1MAPTHPGDKMT2A
SCHEMBL2808770 0.77 TDP1 (0.42) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL5397507 0.77 PTGS2 (0.55) CES1CES2ALDH1A1
SCHEMBL3087344 0.75 CES1 (0.43) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL15437888 0.75 CES1 (0.43) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL7034583 0.75 CES1 (0.43) CES1TDP1MAPK1CYP3A4MAPT
SCHEMBL10348963 0.75 CES1 (0.43) CES1TDP1MAPK1CYP3A4MAPT
Benzoic Acid SCHEMBL6566208 0.73 TSHR (0.82) CES1TDP1MAPK1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5811422-A USEFUL FOR TREATING VIRAL INFECTIONS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-09-22 US disclosed
US-5610294-A VIRAL TREATMENT THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-03-11 US disclosed